However, based on the emerging ECHELON-2 outcomes with the addition of brentuximab vedotin (BV) to an anthracycline-based chemotherapy backbone in CD30-positive PTCL, after two cycles of CHOP, the patient’s chemotherapy regimen was changed to BV-CHP [10,11,12]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.